The Japan presidents of foreign pharma companies are no longer hiding their concerns about the stagnation of drug development in the Japanese market. In their business briefings for 2021, many of them made explicit criticism against what they see as…
ORGANIZATION
JPA Urges MHLW to Allow Access to List of Registered Pharmacies Carrying Lagevrio
Pharmacies in Japan are calling for access to the list of registered pharmacies that carry the oral COVID-19 treatment Lagevrio (molnupiravir). The Japan Pharmaceutical Association (JPA) said that it has made this request to the health minister. The call was…
To read the full story
ORGANIZATION
- JMA President Hopeful Matsumoto Vows to Boost Collaboration with Doctors, Govt; Matsubara Files for Election
May 25, 2022
- JMA Chief Nakagawa Drops Bid for Re-Election, Matsumoto Is Likely Winner
May 24, 2022
- PhRMA Hails Launch of Indo-Pacific Economic Framework
May 24, 2022
- INES-Led Coalition Calls for Patient/Citizen Participation in Healthcare Policymaking
May 23, 2022
- Japan, US, European Pharma Groups Prod Price Maintenance of Patented Drugs in Joint Pitch towards Honebuto
May 17, 2022
The missing ingredient for managers is not their skill, ability, or education. Academic achievements and business success will get runs on the board, to a certain level. However, that is just half of the story.Leaders come in all shapes and…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…